5 Comments
 
Best Response

I'm a healthcare VC, so take my perspective for what it's worth.

BIO is the biggest biotech conference by attendance, and that's not a good thing. Most investors/pharma companies set up one on one meetings through the partnering platform, which is where the real value lies. There will be a lot of biotech industry vendors and mid-level professionals wandering around, who (at least from a VC perspective) are not that useful to go to, and the huge number of people attending makes it hard to network.

If you have a targeted list of individuals who you know are attending (using their web platform), and can set up meetings beforehand, that would be a lot more useful.

Some of the panels may be mildly interesting, but the quality is highly variable and generally lower than conferences such as JP Morgan or the BIO CEO or BIO Investors Conference because of the sheer volume of panels. Some panels can be pretty bad, but the international presence could be one plus.

I'm personally not a fan of the main BIO event. It's fine for partnering, but I wouldn't expect too much from it if you're already in the industry. It might be interesting if you've never worked in industry though in terms of getting a broad overview.

In terms of news flow - not much tends to be announced at BIO - maybe partnerships. Most real news will happen at JPM or the big specialty conferences (ASCO, AACR, etc.).

 
KingPhoenixI'm a healthcare VC, so take my perspective for what it's worth.

BIO is the biggest biotech conference by attendance, and that's not a good thing. Most investors/pharma companies set up one on one meetings through the partnering platform, which is where the real value lies. There will be a lot of biotech industry vendors and mid-level professionals wandering around, who (at least from a VC perspective) are not that useful to go to, and the huge number of people attending makes it hard to network.

If you have a targeted list of individuals who you know are attending (using their web platform), and can set up meetings beforehand, that would be a lot more useful.

Some of the panels may be mildly interesting, but the quality is highly variable and generally lower than conferences such as JP Morgan or the BIO CEO or BIO Investors Conference because of the sheer volume of panels. Some panels can be pretty bad, but the international presence could be one plus.

I'm personally not a fan of the main BIO event. It's fine for partnering, but I wouldn't expect too much from it if you're already in the industry. It might be interesting if you've never worked in industry though in terms of getting a broad overview.

In terms of news flow - not much tends to be announced at BIO - maybe partnerships. Most real news will happen at JPM or the big specialty conferences (ASCO, AACR, etc.).

Awesome information. I'll start setting up some conferences and network extensively.

Thanks KingPhoenix.

 

its kinda useless.

"...the art of good business, is being a good middle man, putting people togeather. It's all about honor and respect."
 

Totam aut magnam nostrum eum nulla doloremque et. Quis facilis quis hic sed.

In recusandae molestiae alias aut ea. Fuga laudantium labore numquam. Deleniti error inventore voluptatem id quaerat iusto. Impedit aut sapiente repudiandae atque. Odio saepe provident nulla commodi. Molestiae alias optio sunt deleniti similique et.

"...the art of good business, is being a good middle man, putting people togeather. It's all about honor and respect."

Career Advancement Opportunities

November 2026 Private Equity

  • Blackstone Group 99.6%
  • The Riverside Company 99.3%
  • KKR (Kohlberg Kravis Roberts) 98.9%
  • Warburg Pincus 98.5%
  • Vista Equity Partners 98.2%

Overall Employee Satisfaction

November 2026 Private Equity

  • Blackstone Group 99.6%
  • KKR (Kohlberg Kravis Roberts) 99.3%
  • The Riverside Company 98.9%
  • Ardian 98.5%
  • Warburg Pincus 98.1%

Professional Growth Opportunities

November 2026 Private Equity

  • Bain Capital 99.6%
  • Blackstone Group 99.3%
  • The Riverside Company 98.9%
  • Starwood Capital Group 98.5%
  • KKR (Kohlberg Kravis Roberts) 98.2%

Total Avg Compensation

November 2026 Private Equity

  • Principal (9) $653
  • Director/MD (24) $547
  • Vice President (100) $364
  • 3rd+ Year Associate (106) $280
  • 2nd Year Associate (236) $272
  • 1st Year Associate (414) $231
  • 3rd+ Year Analyst (33) $157
  • 2nd Year Analyst (97) $134
  • 1st Year Analyst (274) $126
  • Intern/Summer Associate (40) $79
  • Intern/Summer Analyst (357) $61
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”